Key Trends in the Present and Future of Life Sciences Venture

Dr. Krop is a seasoned physician executive with a breadth of drug development experience across multiple therapeutic indications in both pre- commercial and commercial organizations. Most recently, she served as the Chief Medical Officer at Pure Tech Health plc (Nasdaq:PRTC), a clinical stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for people living with high unmet need orphan conditions. Prior to assuming her position with PureTech Health, Dr. Krop served as Chief Medical Officer of Freeline Therapeutics (Nasdaq:FRLN), a clinical stage gene therapy company and the Chief Medical Officer and Executive Vice President of Development, at AMAG Pharmaceuticals (NASDAQ: AMAG) where she successfully oversaw three FDA drug approvals. Previously, Dr. Krop served as the Vice President of Clinical Development for Vertex Pharmaceuticals (NASDAQ: VRTX) where she led development for their Hepatitis C franchise and designed the first proof of concept studies for their pain programs.  Dr. Krop received her B.A. from Brown University and her M.D. from Brown University School of Medicine. She completed her fellowship in the Department of Endocrinology at the Johns Hopkins University School of Medicine, where she was also a Robert Wood Johnson Foundation Clinical Scholar.  Dr Krop has extensive experience successfully designing and executing clinical development programs from early-stage development through FDA approval, and has held senior leadership roles across clinical development, regulatory affairs, clinical operations, pharmacovigilance, medical affairs and program management during her career.  She currently serves on the Board of Directors for Aquestive Therapeutics (NASDAQ AQST) and is a member of the FDA Pulmonary-Allergy Drugs Advisory Committee.

Dr. Kiran Reddy is a Senior Managing Director at Blackstone in the Life Sciences business. At Blackstone he focuses on equity, credit, and structured royalty financings. Dr. Reddy currently serves on the board of directors of Nexstone Immunology, Neurvati, and Nucleus Networks. He also serves on the advisory board of the National Center for Advancing Translational Sciences (NCATS/NIH).Dr. Reddy was previously the President & CEO of Praxis Precision Medicines (NASDAQ: PRAX), which he co-founded. Previously, Dr. Reddy was at Biogen where he was part of the corporate develop and strategy leadership team. Dr. Reddy was an Associate Partner at Third Rock Ventures. He was part of the founding team and Chief Business Officer for SAGE Therapeutics through its IPO and was part of the team that launched Foundation Medicine (acquired by Roche).Dr. Reddy holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard/Massachusetts General Hospital. Dr. Reddy was previously a Howard Hughes science fellow and has authored several peer-reviewed scientific papers in the field of epilepsy, neuroimmunology and neurodegenerative diseases.